Mesothelioma and pancreatic cancer have emerged as initial targets in clinical trials, given their strong association with YAP/TAZ dysregulation and the limited efficacy of existing immunotherapeutic approaches. This evidence concerns the gene YAP1 and familial pancreatic carcinoma.